Gene News and Research

Latest Gene News and Research

New book summarizes current state of research on NF-κB

NF-κB is a critical signaling molecule in the immune system that regulates cell survival and cell death, lymphocyte responses, and inflammation. Acting as a transcription factor that can receive several inputs, it coordinates distinct gene expression programs in response to a wide variety of stimuli.

26 May 2010

Good number of natural bypass vessels an 'insurance policy' against blockage

When the arteries delivering oxygen to our vital organs are obstructed by atherosclerosis or clots, the result is almost always a stroke, heart attack or damage to a peripheral tissue such as the legs (peripheral artery disease). But the severity of tissue injury or destruction from a choked-off blood supply varies from person to person, and may depend in large part on whose circulatory system has the best back-up plan to provide alternate routes of circulation.

26 May 2010

Researchers discover gene mutations in autistic, mentally impaired patients

Researchers working with Professor Gudrun Rappold, Director of the Department of Molecular Human Genetics at Heidelberg University Hospital, have discovered previously unknown mutations in autistic and mentally impaired patients in what is known as the SHANK2 gene, a gene that is partially responsible for linking nerve cells.

26 May 2010

Report: 235 new medicines in development to treat diabetes

A record 235 new medicines to treat diabetes, one of the fastest-growing diseases in America, are being developed by America's pharmaceutical research and biotechnology companies, according to a national report unveiled today in Charleston.

26 May 2010

NIDDK awards Albert Einstein College of Medicine $9.5M for continuation of Diabetes Research and Training Center

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded Albert Einstein College of Medicine of Yeshiva University a five-year, $9.5 million grant for the continuation of its Diabetes Research and Training Center (DRTC). The DRTC was also awarded a $632,000 supplemental grant for equipment and additional pilot and feasibility studies through the American Recovery and Reinvestment Act (ARRA), bringing total NIH support to $10,177,000.

26 May 2010

QIAGEN acquires rights to 70 molecular food safety tests developed by Institute for Product Quality

QIAGEN today announced that it has entered into an agreement with the Institute for Product Quality (ifp), pursuant to which QIAGEN has acquired all rights to 70 molecular food safety tests developed by the Berlin-based specialized laboratory center for food analysis.

From QIAGEN Manchester Limited 26 May 2010

Lumizyme receives FDA approval for patients with late-onset Pompe disease

The U.S. Food and Drug Administration approved Lumizyme (alglucosidase alfa) for patients ages 8 years and older with late-onset (non-infantile) Pompe disease, a rare genetic disorder.

26 May 2010

Epeius Biotechnologies announces Phase I/II study results of Rexin-G and Reximmune-C for cancer immunotherapy

Epeius Biotechnologies Corporation today announces the clinical results of the study entitled "A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol" at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study.

25 May 2010

t2c001 product obtains certificate under EMA regulations for ATMPs

t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the quality of its lead product t2c001 has been certified by the European Medicines Agency.

25 May 2010

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented efficacy, safety and biodistribution results on its new biotherapy AMEP™ for advanced and metastatic melanoma at the 13th Annual Meeting of the American Society of Gene and Cell Therapy in Washington, DC (May 17 - 22, 2010).

25 May 2010

Researchers identify mechanisms involved in gene mutation

Genetic variation due to DNA mutation is a driving force of adaptation and evolution, as well as a contributing factor to disease. However, the mechanisms governing DNA mutation rate are not well understood.

25 May 2010

NIH, FDA launch new portal to provide easier access to online reporting

The Food and Drug Administration and the National Institutes of Health today launched a new Web site that, when fully developed, will provide a mechanism for the reporting of pre- and post-market safety data to the federal government.

25 May 2010

A unique multi-modal atlas of human brain

The Allen Institute for Brain Science announced today that it has launched the Allen Human Brain Atlas, a publicly available online atlas charting genes at work throughout the human brain.

25 May 2010

Scientists develop DNA-vaccine that restricts supply of blood to tumours

A DNA-vaccine that restricts the supply of blood to tumours has been developed by scientists at the Swedish medical university Karolinska Institutet. The vaccine slows the growth of breast cancer tumours in mice.

24 May 2010

Repligen's RG2833 granted orphan drug designation for treatment of Friedreich's ataxia

Repligen Corporation announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation to RG2833, a selective histone deacetylase 3 inhibitor for the treatment of Friedreich's ataxia. Orphan drug designation qualifies Repligen to receive seven years of marketing exclusivity in the United States if the company is the first to obtain marketing approval for RG2833 for the treatment of Friedreich's ataxia.

24 May 2010

BinaxNOW PBP2a test to detect PBP2a in MRSA

AdvanDx today announced that it will offer the BinaxNOW PBP2a test from Inverness Medical Innovations, Inc. (Waltham, MA) to customers in the United States. The test provides rapid detection of the penicillin-binding protein 2a present in Methicillin-Resistant Staphylococcus aureus (MRSA) directly from S. aureus positive blood cultures.

24 May 2010

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

Sangamo BioSciences, Inc. announced today that data from research and preclinical programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in fifteen presentations given by Sangamo scientists and collaborators at the 13th Annual Meeting of the American Society of Gene and Cell Therapy.

24 May 2010

2010 ASCO Annual Meeting highlights new research findings on cancer

Experts from The Cancer Institute at NYU Langone Medical Center will present new research findings at the 46th Annual Meeting of The American Society of Clinical Oncology (ASCO) in Chicago, Illinois.

24 May 2010

Stem cell research could lead to new treatment strategies for motor neuron disease

The Motor Neurone Disease Association is funding its first ever stem cell research programme to help unlock the secrets of this fatal, neurological condition.

24 May 2010

Scientists identify new gene candidates that regulate aggregate formations in Huntington's disease

They might not be known for their big brains, but fruit flies are helping to make scientists and doctors smarter about what causes Huntington's disease and how to treat it. New research, published in the journal GENETICS (http://www.genetics.org) describes a laboratory test that allows scientists to evaluate large numbers of fruit fly genes for a possible role in the formation of plaque-like protein aggregates within cells.

24 May 2010

Gene News and Research

Latest Gene News and Research

New book summarizes current state of research on NF-κB

Good number of natural bypass vessels an 'insurance policy' against blockage

Researchers discover gene mutations in autistic, mentally impaired patients

Report: 235 new medicines in development to treat diabetes

NIDDK awards Albert Einstein College of Medicine $9.5M for continuation of Diabetes Research and Training Center

QIAGEN acquires rights to 70 molecular food safety tests developed by Institute for Product Quality

Lumizyme receives FDA approval for patients with late-onset Pompe disease

Epeius Biotechnologies announces Phase I/II study results of Rexin-G and Reximmune-C for cancer immunotherapy

t2c001 product obtains certificate under EMA regulations for ATMPs

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

Researchers identify mechanisms involved in gene mutation

NIH, FDA launch new portal to provide easier access to online reporting

A unique multi-modal atlas of human brain

Scientists develop DNA-vaccine that restricts supply of blood to tumours

Repligen's RG2833 granted orphan drug designation for treatment of Friedreich's ataxia

BinaxNOW PBP2a test to detect PBP2a in MRSA

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

2010 ASCO Annual Meeting highlights new research findings on cancer

Stem cell research could lead to new treatment strategies for motor neuron disease

Scientists identify new gene candidates that regulate aggregate formations in Huntington's disease

eBook: Using iPSCs models for human disease research and drug discovery eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering